BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schaller TH, Snyder DJ, Spasojevic I, Gedeon PC, Sanchez-Perez L, Sampson JH. First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach. J Immunother Cancer 2020;8:e000213. [PMID: 32273346 DOI: 10.1136/jitc-2019-000213] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Xue T, Wang X, Ru J, Zhang L, Yin H. The inhibitory effect of human umbilical cord mesenchymal stem cells expressing anti-HAAH scFv-sTRAIL fusion protein on glioma. Front Bioeng Biotechnol 2022;10. [DOI: 10.3389/fbioe.2022.997799] [Reference Citation Analysis]
2 Komatsu SI, Kayukawa Y, Miyazaki Y, Kaneko A, Ikegami H, Ishiguro T, Nakamura M, Frings W, Ono N, Sakata K, Fujii T, Kishishita S, Kitazawa T, Endo M, Sano Y. Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial. Sci Rep 2022;12:12312. [PMID: 35853994 DOI: 10.1038/s41598-022-16564-x] [Reference Citation Analysis]
3 Singh K, Hotchkiss KM, Mohan AA, Reedy JL, Sampson JH, Khasraw M. For whom the T cells troll? Bispecific T-cell engagers in glioblastoma. J Immunother Cancer 2021;9:e003679. [PMID: 34795007 DOI: 10.1136/jitc-2021-003679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Aschmoneit N, Kühl L, Seifert O, Kontermann RE. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release. J Immunother Cancer 2021;9:e003616. [PMID: 34782429 DOI: 10.1136/jitc-2021-003616] [Reference Citation Analysis]
5 Lu X, Li C, Xu W, Wu Y, Wang J, Chen S, Zhang H, Huang H, Huang H, Liu W. Malignant Tumor Purity Reveals the Driven and Prognostic Role of CD3E in Low-Grade Glioma Microenvironment. Front Oncol 2021;11:676124. [PMID: 34557404 DOI: 10.3389/fonc.2021.676124] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sun R, Zhou Y, Han L, Pan Z, Chen J, Zong H, Bian Y, Jiang H, Zhang B, Zhu J. A Rational Designed Novel Bispecific Antibody for the Treatment of GBM. Biomedicines 2021;9:640. [PMID: 34204931 DOI: 10.3390/biomedicines9060640] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
7 Gajęcka M, Majewski MS, Zielonka Ł, Grzegorzewski W, Onyszek E, Lisieska-Żołnierczyk S, Juśkiewicz J, Babuchowski A, Gajęcki MT. Concentration of Zearalenone, Alpha-Zearalenol and Beta-Zearalenol in the Myocardium and the Results of Isometric Analyses of the Coronary Artery in Prepubertal Gilts. Toxins (Basel) 2021;13:396. [PMID: 34199438 DOI: 10.3390/toxins13060396] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Gajęcka M, Mróz M, Brzuzan P, Onyszek E, Zielonka Ł, Lipczyńska-Ilczuk K, Przybyłowicz KE, Babuchowski A, Gajęcki MT. Correlations between Low Doses of Zearalenone, Its Carryover Factor and Estrogen Receptor Expression in Different Segments of the Intestines in Pre-Pubertal Gilts-A Study Protocol. Toxins (Basel) 2021;13:379. [PMID: 34073248 DOI: 10.3390/toxins13060379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Tang Y, Cao Y. Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. Pharmaceutics 2021;13:422. [PMID: 33800976 DOI: 10.3390/pharmaceutics13030422] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Gklinos P, Papadopoulou M, Stanulovic V, Mitsikostas DD, Papadopoulos D. Monoclonal Antibodies as Neurological Therapeutics. Pharmaceuticals (Basel) 2021;14:92. [PMID: 33530460 DOI: 10.3390/ph14020092] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
11 Gedeon PC, Champion CD, Rhodin KE, Woroniecka K, Kemeny HR, Bramall AN, Bernstock JD, Choi BD, Sampson JH. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. Expert Rev Clin Pharmacol 2020;13:1147-58. [PMID: 32862726 DOI: 10.1080/17512433.2020.1817737] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]